Ibrutinib continues to outperform chemoimmunotherapy in patients with treatment-naïve CLL ExpertDr Jennifer Woyach, Ohio State University, OH, USA TrialPhase 3, Alliance A041202 ConferenceASH 2021 3 February 2022 23:22